Immunoadsorption ( DrugBank: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	2
14	Chronic inflammatory demyelinating polyneuropathy	1

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04450030 (ClinicalTrials.gov)	August 1, 2018	24/6/2020	Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis	Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis - Assessment of Mechanism of Action	Multiple Sclerosis, Relapsing-Remitting	Drug: Methyl Prednisolonate;Procedure: Immunoadsorption	University Hospital Muenster	NULL	Active, not recruiting	18 Years	65 Years	All	204		Germany
2	EUCTR2017-000635-13-DE (EUCTR)	08/06/2018	22/02/2018	Escalating therapy in steroid-refractory relapses of multiple sclerosis – comparison of methylprednisolone to immunoadsorption	Escalating therapy in steroid-refractory relapses of multiple sclerosis – comparison of methylprednisolone to immunoadsorption	Multiple Sclerosis (MS), acute episode MedDRA version: 20.0;Level: HLT;Classification code 10052785;Term: Multiple sclerosis acute and progressive;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	INN or Proposed INN: Methylprednisolone Other descriptive name: METHYLPREDNISOLONE	Universität Leipzig	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	140	Phase 3	Germany

Clinical trials : 167 / Drugs : 158 - (DrugBank : 38) / Drug target genes : 13 - Drug target pathways : 23

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04881682 (ClinicalTrials.gov)	January 1, 2022	28/4/2021	Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	CIDP	Device: Immunoadsorption;Biological: Immunoglobulins	University of Ulm	Miltenyi Biomedicine GmbH	Not yet recruiting	18 Years	N/A	All	20	Phase 2	Germany